Galantamine vs Donepezil in the Treatment of Alzheimer's Disease...Drugs Aging. 2003;20(10):777-89

Detalles Bibliográficos
Publicado en:Drugs & Aging Vol. 20; no. 15; pp. 1139 - 1141
Autores principales: Goldlist B, Naglie G, Gordon M
Formato: commentary letter Journal Article
Publicado: Springer Nature 2003
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106080846&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 106080846
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        1170229X
        C5B
      jtl: Drugs & Aging
      issn: 1170229X
      maglogo: N
    pubinfo:
      dt: 2003
      vid: 20
      iid: 15
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        106080846
        2009392413
        10.2165/00002512-200320150-00009
        NLM14651439
        106080846
      ppf: 1139
      ppct: 2
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Galantamine vs Donepezil in the Treatment of Alzheimer's Disease...Drugs Aging. 2003;20(10):777-89
      aug:
        au:
          Goldlist B
          Naglie G
          Gordon M
      sug:
        subj:
          Alzheimer's Disease Drug Therapy
          Cholinesterase Inhibitors Therapeutic Use
          Galanthamine Therapeutic Use
          Hydrocarbons Therapeutic Use
          Piperidines Therapeutic Use
          Clinical Trials
      pubtype: Academic Journal
      doctype:
        commentary
        letter
        Journal Article
      ougenre: Article
      ab:
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N